{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"1"}]}],"title":"Hemoglobin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"1"}]}],"title":"Lymphocytes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"}]}],"title":"Neutrophils"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"}]}],"title":"Platelets"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"}]}],"title":"Leukocytes"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.","groups":[{"description":"Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG000","title":"Part 2: GSK525762 60 mg QD CTCL"},{"description":"Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762","id":"OG001","title":"Part 2: GSK525762 75 mg QD MDS"},{"description":"Participants CTCL were administered once daily oral dose of 80 mg GSK525762","id":"OG002","title":"Part 2: GSK525762 80 mg QD CTCL"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population.","reportingStatus":"POSTED","timeFrame":"Up to 36.4 weeks","title":"Part 2: Number of Participants With Grade Change From Baseline in Hematology Parameters","type":"SECONDARY","unitOfMeasure":"Participants"}